Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rexahn Looks For Breakthrough Year With Three Clinical Candidates

Executive Summary

Rexahn Pharmaceuticals hopes this will be its big year. With three candidates in various stages of Phase II development and cash projected to last through the first quarter of 2011, Rexahn feels it should be able to land at least one major deal to either co-develop or out-license one its lead programs
Advertisement

Related Content

Rexahn Adds Drug Conjugate Platform To Its Oncology Offerings
FDA Not Ready For The Nanotechnology Surge; Infrastructure - Not Technical Capability - Is The Challenge, Hamburg Says
FDA Not Ready For The Nanotechnology Surge; Infrastructure - Not Technical Capability - Is The Challenge, Hamburg Says
Slower Deal-Making Year In Oncology Leaves Numerous Appealing Targets
Slower Deal-Making Year In Oncology Leaves Numerous Appealing Targets

Topics

Advertisement
UsernamePublicRestriction

Register

PS051937

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel